Caliber Wealth Management LLC KS Acquires 3,363 Shares of IQVIA Holdings Inc. $IQV

Key Points

• Caliber Wealth Management LLC KS increased its holdings in IQVIA Holdings Inc. by 47.2%, acquiring an additional 3,363 shares during the second quarter, bringing their total to 10,493 shares worth approximately $1.65 million.
• Several brokerages have recently upgraded their ratings for IQVIA, with Evercore ISI raising the price target from $220 to $240, indicating strong investor confidence in the company's prospects.
• IQVIA reported a quarterly earnings per share (EPS) of $2.81, surpassing analysts' expectations of $2.77, and achieved revenue of $4.02 billion, which is a 5.3% year-over-year increase.

Caliber Wealth Management LLC KS grew its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 47.2% in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 10,493 shares of the medical research company's stock after buying an additional 3,363 shares during the quarter. Caliber Wealth Management LLC KS's holdings in IQVIA were worth $1,654,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. Clal Insurance Enterprises Holdings Ltd lifted its stake in IQVIA by 436.7% during the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company's stock worth $28,000 after purchasing an additional 131 shares during the period. Golden State Wealth Management LLC boosted its stake in IQVIA by 295.5% in the 1st quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock valued at $31,000 after buying an additional 130 shares in the last quarter. AllSquare Wealth Management LLC bought a new stake in IQVIA in the first quarter valued at $33,000. Trust Co. of Toledo NA OH acquired a new position in IQVIA during the second quarter worth $39,000. Finally, J.Safra Asset Management Corp lifted its holdings in shares of IQVIA by 208.6% during the second quarter. J.Safra Asset Management Corp now owns 250 shares of the medical research company's stock valued at $39,000 after acquiring an additional 169 shares during the period. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on IQV. Cowen reissued a "buy" rating on shares of IQVIA in a report on Wednesday, July 23rd. Evercore ISI increased their price target on IQVIA from $220.00 to $240.00 and gave the stock an "outperform" rating in a research report on Wednesday, October 8th. HSBC upgraded IQVIA from a "hold" rating to a "buy" rating and lifted their price objective for the company from $195.00 to $235.00 in a research report on Thursday, October 9th. UBS Group increased their target price on IQVIA from $185.00 to $225.00 and gave the stock a "buy" rating in a report on Wednesday, July 23rd. Finally, William Blair reaffirmed an "outperform" rating on shares of IQVIA in a report on Wednesday, July 23rd. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $234.57.

IQVIA Trading Up 3.3%

Shares of NYSE IQV opened at $218.96 on Wednesday. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $231.34. The firm has a market capitalization of $37.22 billion, a P/E ratio of 31.69, a P/E/G ratio of 2.33 and a beta of 1.32. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84. The company's 50 day simple moving average is $192.71 and its 200 day simple moving average is $169.95.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, topping analysts' consensus estimates of $2.77 by $0.04. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The business had revenue of $4.02 billion during the quarter, compared to analysts' expectations of $3.96 billion. During the same period in the previous year, the firm earned $2.64 earnings per share. The firm's quarterly revenue was up 5.3% compared to the same quarter last year. On average, analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.